NAVIDEA BIOPHARMACEUTICALS, INC.: Nasdaq/NYSE listing notice — Navidea receives NYSE American notice over low stock price; board reshuffled

NAVIDEA BIOPHARMACEUTICALS, INC.

NYSE American gave until Dec 1, 2023 to cure low price via reverse split or sustained price improvement.
Entered stock exchange with John K. Scott: 990 Series G preferred shares + $68,853 dividends for 11,969 Series J preferred, subject to approval.
Director Alexander Cappello resigned; Jill Stefanelli, Ph.D. appointed to Board, effective June 1, 2023.
Company amended Keystone Capital purchase agreement to cap issuance at 19.99% of shares unless price ≥ greater of book or market value.
Company remains noncompliant with minimum stockholders' equity requirements from prior NYSE American notices.

item 3.01 item 3.02 item 1.01 item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alexander L. Cappello

Director

NAVIDEA BIOPHARMACEUTICALS, INC.

Effective: 2023-06-01
Successor: Jill Stefanelli
Filed: June 5, 2023, 7:59 PM ET

Effective June 1, 2023, Alexander L. Cappello resigned as a Director of the Company.

Appointed

Jill Stefanelli

Director

NAVIDEA BIOPHARMACEUTICALS, INC.

Effective: 2023-06-01
Filed: June 5, 2023, 7:59 PM ET

The Board appointed Jill Stefanelli, Ph.D. as a Director, effective June 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NAVIDEA BIOPHARMACEUTICALS, INC. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).

Exchange: nyse american
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 1003(f)(v), 1009

Exact text from the filing

June 1, 2023, the Company received a written notice (the “Notice”) from NYSE Regulation (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide because its shares of Common Stock have been selling for a substantial period of time at a low price per share. The Notice has no immediate effect on the listing or trading of the Company’s Common Stock and the Common Stock will continue to trade on the NYSE American under the symbol “NAVB,” although a “below compliance” i

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexander L. Cappello resigned as Director at NAVIDEA BIOPHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

Effective June 1, 2023, Alexander L. Cappello resigned as a Director of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jill Stefanelli was appointed as Director at NAVIDEA BIOPHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

The Board appointed Jill Stefanelli, Ph.D. as a Director, effective June 1, 2023.

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001437749-23-016520

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.